In May 2002, the Women's Health Initiative (WHI) trial of dailycombined therapy with estrogen and progestin was terminatedearly. The reason for stopping was an increased risk of breastcancer (and evidence of greater overall risk than benefit) inthe hormone-therapy group. Far more surprising, however, wasthe associated increase in the risk of myocardial infarction.An expectation of coronary benefit had been a major reason formany women's decisions to use postmenopausal hormone therapy.
Earlier reports had failed to show improvement in cardiovascularoutcomes in postmenopausal women with known cardiovascular diseasewho were treated with conjugated equine estrogen . . . [Full Text of this Article]
Source Information
From the Department of Medicine, Brigham and Women's Hospital, Boston (R.G.D.).
Dr. Solomon adjudicates end points for the Women's Health Initiative.
This article has been cited by other articles:
Comi, R. J.
(2009). Glucose Control in the Intensive Care Unit: A Roller Coaster Ride or a Swinging Pendulum?. ANN INTERN MED
150: 809-811
[Abstract][Full Text]
Figueiredo, J. C., Bernstein, L., Capanu, M., Malone, K. E., Lynch, C. F., Anton-Culver, H., Stovall, M., Bertelsen, L., Haile, R. W., Bernstein, J. L.
(2008). Oral Contraceptives, Postmenopausal Hormones, and Risk of Asynchronous Bilateral Breast Cancer: The WECARE Study Group. JCO
26: 1411-1418
[Abstract][Full Text]
Col, N. F.
(2006). Decision making at the fringe of evidence: take what you can get.. Arch Intern Med
166: 389-390
[Full Text]
Dietel, M., Lewis, M.A., Shapiro, S.
(2005). Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod
20: 2052-2060
[Abstract][Full Text]
Klinge, C. M., Blankenship, K. A., Risinger, K. E., Bhatnagar, S., Noisin, E. L., Sumanasekera, W. K., Zhao, L., Brey, D. M., Keynton, R. S.
(2005). Resveratrol and Estradiol Rapidly Activate MAPK Signaling through Estrogen Receptors {alpha} and {beta} in Endothelial Cells. J. Biol. Chem.
280: 7460-7468
[Abstract][Full Text]
Peterson, H. B., Thacker, S. B., Corso, P. S., Marchbanks, P. A., Koplan, J. P.
(2004). Hormone Therapy: Making Decisions in the Face of Uncertainty. Arch Intern Med
164: 2308-2312
[Full Text]
Cappuzzo, K. A, Delafuente, J. C
(2004). Teriparatide for Severe Osteoporosis. The Annals of Pharmacotherapy
38: 294-302
[Abstract][Full Text]
Hersh, A. L., Stefanick, M. L., Stafford, R. S.
(2004). National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Evidence. JAMA
291: 47-53
[Abstract][Full Text]
Neves-e-Castro, M.
(2003). Menopause in crisis post-Women's Health Initiative? A view based on personal clinical experience. Hum Reprod
18: 2512-2518
[Abstract][Full Text]
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., Hebert, L. A.
(2003). Management of Glomerular Proteinuria: A Commentary. J. Am. Soc. Nephrol.
14: 3217-3232
[Abstract][Full Text]
Ena, G., Rozenberg, S.
(2003). Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod
18: 2245-2248
[Abstract][Full Text]
Doren, M., Nilsson, J.-A., Johnell, O.
(2003). Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod
18: 1737-1746
[Abstract][Full Text]